Key Highlights
- Net loss was about USD 7.4 million versus about USD 4.8 million a year earlier.
- Cash was about USD 0.1 million at September 30, 2026.
- Seven Phase II patients have been dosed in 2026 in STARLIGHT-1.
- The filing discloses substantial doubt about continuing as a going concern.
Loss Widens as Clinical Work Advances
Estrella Immunopharma, Inc. (NASDAQ:ESLA) reported a third-quarter net loss of approximately USD 7.4 million versus approximately USD 4.8 million a year earlier, against an estimated loss of USD 0.08 per share. The company has no revenue, in line with the data set's USD 0.00 estimate.
The filing says it expects Research and Development expenses to continue rising as it works with Eureka to advance regulatory filings, and it records related-party payables and accrued liabilities tied to site activation fees and patient dosing milestones owed to Eureka.
The company describes its payments to Eureka as related-party transactions, which the filing breaks out on the Balance Sheet as payables and accrued liabilities, and it reports a net operating cash use for the nine months.
Total net loss and cash use are tied closely to the trial program, and the filing's Operating Cash Flow discussion names the net loss and the payment of the second site activation fee as the main drivers of cash used.
STARLIGHT-1 Progress
The filing records the "completion of Phase I dosing in the STARLIGHT-1 clinical trial of EB103", announced in November 2025, the company's lead product candidate. In 2026, seven Phase II patients have been dosed in the trial.
The cash flow discussion attributes operating cash use for the nine months mainly to the net loss, together with a reduction of approximately USD 12.5 million in Accounts Payable to a related party after the second site activation fee previously due to Eureka was paid, offset by about USD 0.9 million of additional accrued Liability for patient dosing milestones.
The filing puts the nine-month net loss at approximately USD 12.0 million, with net cash used in Operating Activities of USD 8,695,960 versus USD 1,608,192 a year earlier. Payments of Transaction Costs were USD 758,882 versus USD 52,652.
The prior-year nine-month period included USD 2,400,000 of proceeds from a PIPE Investment in common stock, while the 2026 period shows none, and derivative liabilities of USD 356,505 at December 31, 2025 were absent at September 30, 2026.
Liquidity and Going Concern
At September 30, 2026, the company had cash and cash equivalents of approximately USD 0.1 million and a Working Capital Deficit of about USD 14 million. Management has determined that there is substantial doubt about its ability to continue as a going concern.
Total current liabilities were USD 15,642,730 versus USD 13,543,033 at December 31, 2025, and the filing shows no non-current liabilities, so the entire liability balance sits within the current section.
Items to Follow
Reference points include further dosing milestones owed to Eureka, the working capital deficit, the pace of research spending and any financing described in the Liquidity section of the next filing.
The filing's liquidity discussion also covers the deferred obligations to Eureka, which sit within the working capital deficit.






Please wait processing your request...